Daniel G Nicastri
Articles
-
Jul 31, 2024 |
cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more
A group of experts discuss the current treatment algorithm for NSCLC, as well as novel approaches under investigation, the impact of molecular biomarkers on their treatment decisions, and the importance of clinical trials.
-
Jul 31, 2024 |
A group of experts discuss the current treatment algorithm for NSCLC, as well as novel approaches under investigation, the impact of molecular biomarkers on their treatment decisions, and the importance of clinical trials.
-
Jul 31, 2024 |
cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more
Fred R. Hirsch, MD, PhD, leads a discussion with his Mount Sinai colleagues about important biomarkers found in non-small cell lung cancer, including those that provide predictive and prognostic information.
-
Jul 31, 2024 |
Fred R. Hirsch, MD, PhD, leads a discussion with his Mount Sinai colleagues about important biomarkers found in non-small cell lung cancer, including those that provide predictive and prognostic information.
-
Jul 31, 2024 |
cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more
Helping patients manage potential treatment-related adverse events is an essential part of the overall care plan in the treatment of non-small cell lung cancer. Experts provide strategies to address adverse events and best practices for providing the supportive care needed for patients.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →